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ABSTRACT 
Objective: This study was designed to investigate the impacts of administering of different concentrations of Aqueous Green Tea Extract (AGTE) 
(0.625, 1.25 or 2.5%) during Methotrexate (MTX) treatment, and continued for 5 days, on blood indices in rats.  
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Methods: Six groups of white Albino rats were utilized:  Group I- (Control, received water); Group II- [single i. p. injection (20 mg/kg) of MTX], 
Group III- [1.25% concentration of AGTE alone for 5 days], and Groups IV, V and VI- [rats were administered, respectively AGTE (0.625, 1.25 or 
2.5%), during MTX treatment, and continued for 5 days].  
Results: The results showed that MTX alone induced significant decreases in Hb, HCT, MCHC, MCH, RBCs, and total WBCs;  while, it increased 
platelets count. Administration of different concentrations of AGTE during MTX produced significant decrease in total WBCs and platelets;  while 
significant increase in Hb, HCT, MCHC, MCH;  meanwhile, significant increase, or decrease, respectively in MCV (depending on the concentration of 
AGTE); and a significant increase in RBCs only was seen at 2.5% AGTE plus MTX), compared to MTX-treated animals.  
Conclusion: Marked alterations in blood indices were obtained from this study when AGTE was administered during MTX treatment. So this study 
recommends taking into account such administration when MTX is therapeutically utilized. 
Keywords: Methotrexate, Aqueous Green tea extract, Blood indices, Rats. 
 
INTRODUCTION  
Methotrexate (MTX), a dihydrofolate analog, inhibits dihydrofolate 
reductase enzyme, an enzyme that is important for conversion of 
dihydrofolate to tetrahydrofolate. Thus, MTX treatment causes 
depletion of folate stores [1, 2]. The drug is widely used for the 
treatment of various malignancies as well as in the treatment of 
rheumatoid arthritis and other chronic inflammatory disorders [3-
5]. Along with its effective therapeutic power, MTX has adverse 
effects on several organs and tissues [6-9]. Green tea, made from 
the dried leaves of (Camellia sinensis, Theaceae) is one of the most 
popular beverages consumed around the world. Numerous 
experimental and epidemiological studies support the health 
benefits of green tea consumption, including chemo-preventive 
properties [10, 11], anti-inflammatory effects and antioxidants 
that scavenge free radicals to protect cells in normal and 
pathological states [12]. Most of the beneficial effects of green tea 
are attributed to its polyphenolic flavonoids, known as catechins, 
including epicatechin (EC), epigallocatechin (EGC), epicatechin-3-
gallate (ECG) and the major flavonoid (−)-epigallocatechin-3-
gallate (EGCG (One cup (240 ml) of brewed green tea contains up 
to 200 mg EGCG) [13]. The haematological adverse effects that 
provoked by the chemotherapeutic drug MTX may be possibly 
influenced by the administration of green tea.  There was no 
previously performed study to elucidate the impacts of 
administering different concentrations of AGTE during MTX on 
blood indices. Thus, the aim of this study was to investigate the 
impacts of administering of (0.625, 1.25 or 2.5%) concentration 
AGTE during MTX treatment, and continued for 5 days on some 
selected blood indices in rats. 
MATERIALS AND METHODS 
Preparation of Aqueous Green Tea Extract (AGTE) 
Different concentrations of AGTE (0.625, 1.25, and 2.5%) were 
freshly prepared by soaking for 10 minutes 0.625  gm, 1.25  gm and 
2.5  gm, respectively of green tea leaves in 100 ml of distilled water 
at 90oC;  then each solution of AGTE was filtered [14]. The aqueous 
extract was substituted water as the sole source of drinking fluid in 
animals administered only 1.25% AGTE, and in groups of animals 
administered 0.625, 1.25, or 2.5% AGTE during MTX, and continued 
for 5 days). 
Experimental protocol  
Thirty-six White Albino rats of both sexes, weighing 200-220g were 
used in this study;  the animals were obtained from and maintained 
in the Animal House of the College of Pharmacy, University of 
Baghdad under conditions of controlled temperature.  
The animals were fed commercial pellets. Groups of animals that 
selected and served as control or those treated with MTX alone were 
allowed access to tap water ad libitum;  the remainder groups of 
animals that utilized in this study were allowed access to specific 
concentrations of AGTE as their sole source of drinking fluid. Ethical 
Committee in the College of Pharmacy, University of Baghdad was 
approving this study.  
Rats were divided into six groups of six animals each:  
I- Animals were administered water this group served as negative 
control. 
II- Methotrexate was administered to rats in a dose of 20 mg / kg, i. 
p., for one day. Following this dose, saline was administered for 5 
consecutive days [15].  
III- Aqueous green tea extract (AGTE) alone, at a concentration of 
1.25%, was given to group of animals as a sole source of drinking 
water for 5 consecutive days.  
IV, V, and VI- Groups of animals was received respectively, different 
concentrations (0.625, 1.25 or 2.5%) of AGTE, as their sole source of 
drinking water, during MTX treatment, and continued for 5 days 
[14].  
International Journal of Pharmacy and Pharmaceutical Sciences 




Int J Pharm Pharm Sci, Vol 6, Issue 9, 175-178 
176 
Analysis of Blood Indices 
Animals were sacrificed by cervical dislocation 24 hours after the 
end of the treatment (at day 6). Blood was obtained from each 
animal via intra-cardiac puncture and put in EDTA-containing tubes 
for analysis of selected indices [hemoglobin (Hb), hematocrit (HCT), 
mean corpuscular Hb concentration (MCHC), mean corpuscular 
hemoglobin (MCH), red blood cell (RBCs) counts, total white blood 
cell (WBCs) counts and platelet counts] utilizing auto- haematology 
analyzer (Mindray BC 2800). The measure of mean corpuscular 
volume (MCV) is attained by multiplying a volume of blood by the 
proportion of blood that is cellular HCT, and dividing that product by 
the number of RBCs in that volume [16]. 
The significance of differences between two mean values was 
calculated using unpaired Student's t-test. Descriptive data were 
analyzed depending upon the one way Analysis of Variance 
(ANOVA) to compare the results among the various groups. Data 
were expressed as mean± SEM. P-values less than 0.05 (P<0.05) 
were considered significant for the data presented in the results of 
the current study.  
RESULTS 
Single IP injection of 20mg/kg MTX to rats caused significant 
decrease (P<0.05) in levels of Hb, HCT, MCHC, MCH, reduction in 
numbers of RBCs and total WBCs;  while significant (P<0.05) 
increase in platelets count was observed compared to negative 
control group. Tables 1 and 2. 
Oral administration of 1.25% AGTE alone to rats for 5 days 
produced non-significant differences (p > 0.05) in levels of [Hb, HCT, 
MCV, MCHC, and RBCs]; while, significant differences (P<0.05) were 
observed in levels of [MCH, WBCs, and platelets counts] compared to 
negative controls as shown in tables 1 and 2. 
Rats received different concentrations of AGTE (0.625, 1.25 or 
2.5%), as their sole source of drinking water during MTX treatment, 
and continued for 5 days, produced significant (P<0.05) alterations 
in some blood indices compared to MTX-treated. There was a 
significant increase (P<0.05) in the level of Hb in groups of rats co-
administered either 1.25, or 2.5% AGTE with MTX compare to MTX-
treated animals. Haemoglobin (Hb) levels in the previously-
mentioned groups being non-significantly different (P>0.05) with 
that of negative control. While, in 0.625% AGTE group, there was 
non-significant (P>0.05) in the level of Hb compared to MTX-treated 
rats. Table 1. 
Rats orally-administered with either (1.25%, or 2.5%) of AGTE 
during MTX treatment, and continued for 5 days, produced 
significant increase (P<0.05) in levels of HCT compared to MTX-
treated rats;  while, non-significant difference in the level of HCT in 
group of rats administered 0.625% AGTE during MTX treatment, 
and continued for 5 days, was observed compared to MTX-treated 
animals. Table 1. 
Concerning MCV, significant increase in such blood index was 
produced in rats orally-administered 0.625% and 1.25% AGTE 
concentrations;  while, significant decrease in MCV was observed in 
the animals orally-administered 2.5% AGTE concentration during 
MTX treatment, and continued for 5 days compared to MTX-treated 
rats. 
Concerning MCHC, rats orally-administered with either (0.625%, or 
1.25%) of AGTE during MTX treatment, and continued for 5 days, 
produced non-significant differences (P>0.05) in such 
concentration;  while, a significant difference (P<0.05) in MCHC in 
rat administered 2.5% AGTE during MTX treatment, and continued 
for 5 days, compared to MTX-treated rats. Table 1. 
There were the significant increase (P<0.05) in MCH index in groups 
of rats orally-administered with either (0.625%, 1.25% or 2.5%) 
AGTE during MTX treatment, and continued for 5 days, compared to 
MTX-treated rats. Table 1. 
Concerning RBCs counts, rats orally-administered with 2.5% AGTE 
during MTX treatment, and continued for 5 days, produced 
significant increase (P<0.05) in such count compared to MTX-
treated and negative control rats. Moreover, there was a significant 
increase (P<0.05) in such counts in rats orally-administered with 
1.25% AGTE during MTX treatment, and continued for 5 days 
compared to MTX-treated rats. The RBCs counts were non-
significantly (P>0.05) different compared to that of negative control 
animals. While, no significant differences (P>0.05) in RBCs counts in 
rat administered 0.625% AGTE during MTX treatment, and 
continued for 5 days, compared to MTX-treated rats. Table 2. 
There were significant decrease (P<0.05) in total WBCs and platelets 
counts in rat administered either 0.625, 1.25 or 2.5% AGTE during 
MTX treatment, and continued for 5 days, compared to MTX-treated 
and to negative control groups, as shown in table 2. 
DISCUSSION 
Data obtained from the current study showed that there were 
alterations in blood indices-induced by MTX in rats manifested by 
decline in all the studied corpuscular indices and blood cells counts 
(except platelets counts, where an elevation in platelets number 
were observed in the present study in contrast to that observed by 
other investigators) [17].  
The alterations in the blood indices-induced by the drug may be 
related to the depletion of tetrahydro folic acid (THFA) as a 
consequence of the inhibitory property of MTX on dihydrofolate 
reductase (DHFR) [18] leading to inhibition of purine and 
pyrimidine metabolism, which in turn causing inhibition of DNA and 
RNA synthesis [19], limiting cell division, hindering of 
erythropoiesis [20].  
It has been reported that such metabolic alterations are responsible 
for both the therapeutic and the toxic effects of MTX [21]. Moreover, 
the toxic effects of the drug was attributed to its action on the S-
phase of the cell-cycle and by this action, it affects tissues with high 
turnover such as bone marrow [22]. Therefore, the risk involved 
with the use of MTX on the haematological system is high. One of the 
most common adverse effects caused by MTX is the reduction in 
WBCs counts and thus predisposition to infection. Additionally, it 
has been reported that MTX produced a significant reduction in the 
antioxidant enzyme levels and thus sensitizing cells to ROSs [23]. 
Erythrocytes are particularly susceptible to oxidative damage as a 
result of high polyunsaturated fatty acid (PUFA) content in their 
membranes and high concentration of oxygen and Hb, the latter 
being a potentially powerful promoter of oxidative processes [24].  
The alterations in the above mentioned blood indices induced by 
MTX may possibly be influenced by the administration of green tea, 
which is one of the most popular beverages consumed around the 
world and have various characteristics behavior [25-27]. 
The results of the current study showed that significant increase in 
the levels of Hb, HCT, MCHC, and RBCs in group of rats treated with 
1.25% AGTE alone;  also, there were marked increases in total WBCs 
and platelets counts compared to both negative control and MTX-
treated animals. The elevation in the previously-mentioned blood 
indices after 1.25% AGTE might be related to the antioxidant 
properties of the extract catechines on haematopoietic cells [28]. 
Such concentration of AGTE, (1.25%) utilized in the current study 
produced comparable beneficial antioxidant effects to that observed 
by others [14].  
Depending on the concentration of AGTE that was utilized, the 
present study revealed that the administration of 0.625, 1.25, or 
2.5% of AGTE during MTX treatment, and continued for 5 days, 
produced an improvement in some blood indices (Hb, HCT, MCHC, 
MCH, and RBCs); and deleterious impacts on others (WBCs, and 
platelets counts). A striking result obtained from this study showed 
that an elevation in MCV (an indicator of hematologic toxicity), is 
manifested only after the administration of either 0.625% or 1.25% 
of AGTE during MTX;  but not observed after that of 2.5% AGTE with 
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MTX, where the latter combination produced a reduction in 
MCVcompared to MTX-treated and to both 1.25% AGTE alone-
treated and control groups, this may be attributed to unknown 
mechanism. 
 
Table 1: Blood indices (Hb, HCT, MCV, MCH, and MCHC) levels among groups of rats, ((negative control, methotrexate (MTX)-treated, 
1.25% aqueous green tea extract (AGTE) alone, and AGTE concentrations administered (0.625, 1.25 or 2.5%) during MTX treatment)), 
and continued for 5 days. 







MTX plus AGTE 
0.625%(n=6) 
MTX plus GTE 
1.25%(n=6) 
MTX plus AGTE 
2.5%(n=6) 
Hemoglobin (gm/dl) 13.04 ± 0.23 11.7± 0.23 a 13.5± 0.18 * b a 12.25± 0.24  14.5± 0.27* b 14.4± 0.2 * c *c 
Hematocrit (HCT) (%) 43.1± 0.8 a 38.6± 0.56   42.0 ± 1.1 * b 37.6± 1.1 a 48.3± 1.09 *b 44.4± 1 * c 
Mean corpuscular volume 
(MCV) (fL) 
a 
58.24 ± 0.54 57.61± 0.55 a 55.92± 0.67 a 61.43± 0.61 a 63.72± 0.58 *b * 47.74± 0.57 b 
mean corpuscular Hb (MCH) 
(pg) 
*c 




32.2± 0.8 Pa 31.6± 0.91P*b 32.6± 0.75 Pa 31.0± 0.63 Pb 30.1± 0.9 Pb 32.6± 1.18 Pa 
Data are presented as mean ± SEM, n= number of animals, *P<0.05: significant difference with respect to control group, Values with non-identical 
superscripts (a, b, and c) among different groups considered significantly different, P<0.05, MTX-treated = methotrexate-treated rats, 1.25% AGTE= 
1.25% aqueous green tea extract alone. 
 
Table 2: Blood cells counts among groups of rats, ((negative control, methotrexate (MTX)-treated, 1.25% aqueous green tea extract 
(AGTE) alone, and AGTE concentrations administered (0.625, 1.25 or 2.5%) during MTX treatment)), and continued for 5 days. 







MTX plus AGTE 
0.625%(n=6) 
MTX plus GTE 
1.25%(n=6) 
MTX plus AGTE 
2.5%(n=6) 
Red blood cells (RBC) 
(×10P6P cells/μl) 
7.4+0.17 Pa 6.7± 0.19 P* b 7.51± 0.19 Pa 6.12± 0.25 P*b 7.58± 0.15 Pa 
 
9.3± 0.15 P*c 
Total white blood cells 
(WBC) (×10P3P cells/μl) 
9.24± 0.54 Pa 7.5± 0.41*Pb 13.4± 0.9 P*c 5.7± 0.65 P*d 3.0± 0.23 P*e 5.26± 0.57 P*d 
Platelets  
(×10P3P cells/μl) 
438.5± 20.32 Pa 450± 18.8 P*b 428.8± 18.05 P*c 151.2± 19.55 P* d 123.0± 17.8P* e 112± 15.67 P* f 
Data are presented as mean ± SEM, n= number of animals, *P<0.05: significant difference with respect to control group, Values with non-identical 
superscripts (a, b, c, d, e, and f) among different groups considered significantly different, P<0.05, MTX-treated = methotrexate-treated rats, 1.25% 
AGTE= 1.25% aqueous green tea extract alone. 
 
It has been reported that, although green tea and its constituents, 
catechines possess antioxidant properties and have health benefits, 
but, they led to increase production of reactive oxygen species 
(ROSs) and increased intracellular oxidative stress in vitro [26] and 
in vivo [27]. Besides, the ester-bonded gallate catechins from green 
tea, such as EGCG and ECG, are considered as potent in vitro 
inhibitors of several DHFRs at concentrations found in the serum 
and tissues of green tea drinkers (0.1–1.0 M); and consumption of 
large amounts of green tea could decrease the activity of 
dihydrofolate reductase enzyme (DHFR) [25, 29-30].  
CONCLUSION 
According to the results obtained from this study, one can conclude 
that AGTE alone has an opposite impact on selected blood indices 
measured in this study compared to that produced by MTX. 
Furthermore, marked impacts in RBCs. WBCs, and platelets counts 
were observed in a group of rats administered AGTE during MTX 
compared to MTX-treated group. This study provide the first 
evidence concerning the impacts of the concentrations of AGTE 
utilized in this study (0.625, 1.25, or 2.5%) administered during 
MTX, and thus, it warned about the administration of different 
concentrations of AGTE with MTX when it is therapeutically utilized, 
due to marked alterations in haematological indices. Further studies 
are needed to confirm the finding of the current study. 
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